Enhancer of zeste homology 2 (Ezh2), an epigenetic regulator: A possibility for prostate cancer treatment

Sanjay Kumar, James A. Stokes, Udai P. Singh, Kumar S. Bishnupuri, Manoj K. Mishra

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Mounting evidence of epigenetic dysregulation in cancer development has received lots of attention from cancer researchers and physicians. Enhancer of zeste homology 2 (Ezh2), an epigenetic regulator, plays an important role in cellular growth and survival. Ezh2 is a catalytic core protein, which belongs to Poly comb Repressor Complex 2 (PRC2). Ezh2 encodes histone methyltransferase, which induces the trimethylation of histone3 lysine27 (H3K27) and is involved in gene repression. The expression of Ezh2 is increased in breast, colon, lung, pancreatic and prostate cancer. Increased expression of Ezh2 is associated with the development and progression of malignant cancers, especially with the prostate cancer. Therefore, studies on Ezh2 inhibition have added more focus towards drug discovery and development to combat cancers. Thus, this offers great potential for the development of second-generation cancer therapies. Therefore, in this chapter we provide an analysis of novel cancer treatment methods that target epigenetic factors such as Ezh2. We will examine key examples of Ezh2 regulation in prostate cancer as well as novel drug concepts that employ epigenetic targets. This chapter will also provide a glimpse of recent successes in cancer epigenetic drug discovery and consider important epigenetic factors for scientific success in combating cancer.

Original languageEnglish
Title of host publicationEpigenetic Advancements in Cancer
PublisherSpringer International Publishing
Pages229-244
Number of pages16
ISBN (Electronic)9783319249513
ISBN (Print)9783319249490
DOIs
StatePublished - Jan 1 2016

Keywords

  • Apoptosis
  • Chromatin
  • Ezh 2
  • Prostate cancer therapy
  • Tumor suppressor

Fingerprint Dive into the research topics of 'Enhancer of zeste homology 2 (Ezh2), an epigenetic regulator: A possibility for prostate cancer treatment'. Together they form a unique fingerprint.

  • Cite this

    Kumar, S., Stokes, J. A., Singh, U. P., Bishnupuri, K. S., & Mishra, M. K. (2016). Enhancer of zeste homology 2 (Ezh2), an epigenetic regulator: A possibility for prostate cancer treatment. In Epigenetic Advancements in Cancer (pp. 229-244). Springer International Publishing. https://doi.org/10.1007/978-3-319-24951-3_10